In collaboration with CPI’s Medicines Manufacturing Innovation Centre, PharmaTech Integrates brings together experts in disruptive advanced medicines manufacturing and digital technologies. This event engages the broadest possible network of pharmaceutical innovators, regulators, supply chain partners, equipment and technology providers, academia, and industry associations.
In 2025, the pharma industry is facing unprecedented change, with the emergence of increasingly complex, but highly effective therapeutic modalities driven by ever more sophisticated understanding of genomics and the fundamental causes of disease. This is coupled with the disruptive force of the information age, promise of AI and manifold other technology advances that hold immense promise, but can be challenging to deploy in the ‘real world’.
PharmaTech Integrates 2025 will explore these themes and discuss how these trends can be brought together to deliver the industry of the future.
Siemens
Vice President Vertical Management Pharma
I am passionate about creating and developing successful teams, and empowering people through servant and values-based leadership. My mission is to help our customers and partners achieve their goals and optimize their performance with our integrated, intelligent, and comprehensive portfolio of solutions.
Strathclyde Institute for Pharmacy and Biomedical Sciences, University of Strathclyde
Chair in Drug Delivery
Professor Yvonne Perrie is the Chair in Drug Delivery within Strathclyde Institute for Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland. Prior to this appointment, she was Professor in Drug Delivery, within Aston University, Birmingham, England (2007-2016). Yvonne has a BSc (First-Class Hons) in Pharmacy from Strathclyde University and she attained her PhD from the University of London under the supervision of Prof Gregoriadis. Yvonne’s research is multi-disciplinary and is focused on the development of drug carrier systems to facilitate the delivery of drugs and vaccines, providing practical solutions for current healthcare problems. Yvonne has published approximately 150 peer-reviewed papers, 5 patents and 4 text books. She is a Fellow of the Society of Biology, a Fellow of the Royal Society of Chemistry, the Royal Pharmaceutical Society, a member of the College of Fellows for the Controlled Release Society, and an Eminent Fellow of the Academy of Pharmaceutical Sciences. Yvonne was appointed a Member of the Order of the British Empire (MBE) in His Majesty the King’s New Year Honours List 2024 for services to pharmaceutical innovation and regulation.
AI has evolved from a promising innovation to a transformational force in pharmaceutical R&D, manufacturing and supply chain optimisation. But as the industry moves beyond early adoption, the big questions remain—how effective is AI in practice, and where are the real opportunities for impact?
How can pharmaceutical businesses ensure they are integrating necessary digital and data infrastructure effectively? More importantly, how does this translate into tangible benefits for quality, compliance and operational efficiency, whilst remaining sustainable?
Plvs Ultra
Director
Highly experienced digital leader with an entrepreneurial passion for delivering disruptive change to achieve high value strategic objectives through technology. 31 years of Pharmaceutical Industry experience, holding Pharma Sciences BSc, spending first half of the career developing, making, introducing and supplying pharmaceutical products and the second half innovating and leading the introduction of disruptive Digital, Data and AI solutions. Founder of Pivot-DC Ltd and cofounder of Plvs Ultra Ltd.
As the industry faces mounting pressure to boost efficiency, minimise waste and strengthen supply chain resilience, process intensification is emerging as a game-changer for pharma manufacturing. This panel will explore how advanced process technologies, from continuous manufacturing to micro-factories, are reshaping production. But what are the barriers to widespread adoption, and how can the industry navigate the challenges ahead?
Some advanced therapies are produced with highly labour-intensive but repetitive processes. Automated manufacturing is promising to deliver dramatic productivity and reproducibility improvements, along with significant enhancements to return of capital, but will it deliver? What role can robotics play in the production of pharmaceuticals of the future?
University of Strathclyde
Director, Continuous Manufacturing and Advanced Crystallisation (CMAC) Research Hub
Professor Alastair Florence is Distinguished professor in pharmaceutical sciences at the University of Strathclyde and Director of CMAC leading a portfolio of collaborative research, training and translational programmes aimed at transforming the way medicines are developed and manufactured. Manufacturing research is targeted in enabling greater use of digital and advanced processing technologies. He leads several flagship projects including the EPSRC Future CMAC Research Hub and recently announced Made Smarter Innovation Digital Medicines Manufacturing Research Centre. The portfolio is being delivered in close partnership with leading industrial partners from across pharmaceutical manufacturing sector and academic collaborators.
His research expertise is in crystallisation and physical form control and characterisation of pharmaceuticals. Extensive experience in the formation of pharmaceutical particles in continuous processes using a range of technologies and in the development and application of digital tools and predictive methods to control and monitor crystallisation and pharmaceutical solids. Approaches for the characterisation of particles are also widely used and physical analysis of crystalline pharmaceuticals with a focus on the influence of crystallisation processes on structure and critical pharmaceutically relevant attributes that dictates product performance. Has published over 120 peer reviewed research papers in these areas and currently supervises a large multidisciplinary research group.
The concept of truly personalised therapies is often talked about but seldom delivered. How can emergent pharma technologies support the delivery of truly tailored therapies, to bring outstanding patient outcomes?
PwC
Partner
To follow
For 2025, we will be running sessions at CPI’s Medicines Manufacturing Innovation Centre (MMIC).
The Medicines Manufacturing Innovation Centre was created by CPI to develop, prove and commercialise disruptive technologies for the pharmaceutical industry. Click here to view map and driving directions to the Medicines Manufacturing Innovation Centre.
Click here to see full Public Transport and Parking Details.
Advanced Manufacturing Innovation District Scotland (AMIDS), Netherton Square, Paisley, Glasgow, PA3 2EF
